Immune Regulation explores whether IRL201104 has a potential role to play in treatment of COVID-19
COVID-19 the overwhelming potential pathology with those at highest risk to COVID-19 infection is uncontrolled activation of the immune system to combat infection, particularly overactivation of neutrophils. However, in the vulnerable, the action of these mediators lead to the destructive inflammation that can lead to overwhelming inflammation, leading to death. This outcome could be a result of the inflammatory response itself, or through the inability to fight off other respiratory bacterial of viral infections. Hence, a key element of timing, is to allow neutrophils to combat the virus, but not to induce overwhelming inflammation.
IRL201104 is not an approved or marketed drug or vaccine, but may potentially be a therapeutic approach that could be used preventatively to slow down ICU admissions if used at the right time. Immune Regulation are in touch with the relevant authorities concerning whether any investigational use of IRL201104 should be considered.
IRL201104 has been shown to quickly and markedly reduce lung infiltration of neutrophils in mice following bronchial challenge with lipopolysaccharide stimulating acute neutrophil activation. IRL1104 has a very short circulation exposure following IV administration and acts on neutrophil infiltration quickly but in a transient manner, which may mean that it would be able to provide a marked, but temporary, reduction in lung neutrophilia, potentially allowing the lung some respite from the high level of inflammation.